Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of sufentanil for induction intubation in patients with different pain sensitivities
ChiCTR2400087707Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sufentanil in thyroid disease (3 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: ED50 and ED95 of sufentanil required for induction of anesthesia for tracheal intubation in different pain sensitivity groups. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
sufentanil
03
Conditions
thyroid disease
Beyond the preview
Go deeper on ChiCTR2400087707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087707.